Previous Close | 6.10 |
Open | 6.05 |
Bid | 6.21 x 600 |
Ask | 6.27 x 400 |
Day's Range | 5.93 - 6.26 |
52 Week Range | 1.25 - 10.53 |
Volume | |
Avg. Volume | 7,079,684 |
Market Cap | 4.315B |
Beta (5Y Monthly) | -0.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.08 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.50 |
CULVER CITY, Calif., June 07, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting.
CULVER CITY, Calif., May 17, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research.
ImmunityBio ( NASDAQ:IBRX ) First Quarter 2024 Results Key Financial Results Net loss: US$134.1m (loss widened by 15...